ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ANGLE reports that its order book remains robust, citing 2022 as a year of significant progress.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
Angle PLC Pharma Services Contract with Crescendo Biologics
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
Brazil football legend Pele under palliative care amid cancer battle
SAO PAULO, Dec 3 (Reuters) – Brazilian soccer legend Pele is receiving palliative care after the chemotherapy stopped having the expected results as he battles colon cancer, newspaper Folha de
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Angle PLC (AIM:AGL) receives FDA clearance for Parsortix
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM
Angle PLC (AIM:AGL) Identifying therapeutic targets in TNBC patients
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
Green light for small cell lung cancer treatment given to AstraZeneca in China
Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted